logo

For the Inventor, By the Inventor

Los Angeles, CA, United States of America

Dermot McGovern

This inventor holds 8 USPTO granted patents and 6 published patent applications. Top assignees: Cedars-Sinai Medical Center, Prometheus Biosciences, Inc., Qu Biologics Inc.. Active years: 2017-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dermot McGovern. Retrieved from https://idiyas.com/inventor/dermot-mcgovern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8 

% Patents Active = 87.5

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 52(Granted Patents)


Company Filing History:

goldMedal7 out of 628 
 
Cedars-Sinai Medical Center
 patents
silverMedal1 out of 15 
 
Prometheus Biosciences, Inc.
 patents
bronzeMedal1 out of 13 
 
Qu Biologics Inc.
 patents
where one patent can have more than one assignee

Years Active: 2017-2024

Loading Chart...
8 patents (USPTO):Explore Patents
1. 12018086 - Kit comprising contiguous nucleobases, including position 76, of RS5745994 (2024-06-25),
2. 11226340 - Therapeutically triggering an innate immune response in a target tissue (2022-01-18),
3. 11186872 - Methods of diagnosing inflammatory bowel disease through RNASET2 (2021-11-30),
4. 11180565 - Method of enriching a target nucleic acid at a TNFRSF1B gene locus in a sample from a subject with inflammatory bowel disease (2021-11-23),
5. 11136386 - Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) (2021-10-05),
6. 10626180 - Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease (2020-04-21),
7. 9902996 - Methods of predicting the need for surgery in crohn's disease (2018-02-27),
8. 9580752 - Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy (2017-02-28),

Title: Innovator Dermot McGovern: Pioneering Advances in Immunotherapy

Introduction

Dermot McGovern, based in Los Angeles, CA, is a noteworthy inventor with a remarkable portfolio of eight patents. His work primarily focuses on innovative therapeutic strategies that have significant implications in the medical field, particularly in immunotherapy and the treatment of inflammatory diseases.

Latest Patents

Among his latest patents, McGovern has made groundbreaking contributions, including a kit comprising contiguous nucleobases associated with the RS5745994 gene. This invention provides vital methods for identifying subjects who are non-responsive to anti-TNF therapy, enhancing treatment methodologies for individuals suffering from Inflammatory Bowel Disease (IBD). Additionally, he has introduced a patent on therapeutically triggering an innate immune response within target tissues. This invention presents novel therapeutic compositions that harness an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists. These compositions aim to modulate immune responses effectively, forming a crucial part of the therapeutic approach against various pathologies.

Career Highlights

Dermot McGovern has collaborated with renowned medical institutions, including Cedars-Sinai Medical Center and Prometheus Biosciences, Inc. His career has been marked by a commitment to advancing healthcare solutions through innovative research and development. McGovern’s contributions have been essential in bridging gaps in current therapies and fostering new avenues for patient treatment.

Collaborations

Throughout his career, McGovern has worked alongside esteemed colleagues such as Stephan R. Targan and Dalin Li. These collaborations have played a significant role in the development of his patents, emphasizing a collaborative approach toward tackling complex health challenges.

Conclusion

Dermot McGovern stands out as an influential figure in the realm of medical innovation. With his significant patent portfolio and collaborative efforts in prominent medical institutions, he continues to impact the field of immunotherapy and beyond. His inventions not only enhance our understanding of immune responses but also pave the way for improved therapeutic interventions in the treatment of inflammatory diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…